ASH 2017 | Genetic heterogeneity in AML: the reasoning behind targeting FLT3 and IDH
Researchers and clinicians now recognize that AML comprises a multitude of subtypes. In this interview, Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses our current understanding of the biology of acute myeloid leukemia (AML). In particular, Dr Stone covers the mechanisms of action the disease subverts when FLT3 or IDH is mutated, and how we can target this heterogeneity. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Get great new content delivered to your inboxSign up